Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 1/20 | 0.78 |
| ▸ | KDR | P35968 | 18/20 | 0.67 |
| ▸ | FLT1 | P17948 | 13/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.67 |
| ▸ | KIT | P10721 | 11/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | FLT4 | P35916 | 2/20 | 0.58 |
| ▸ | CIT | O14578 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | HLA-A | P04439 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.58 |
| ▸ | FRK | P42685 | 1/20 | 0.58 |
| ▸ | CDK8 | P49336 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.58 |
| ▸ | STK3 | Q13188 | 1/20 | 0.58 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.58 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.58 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17792704 | 0.88 | SHMT2 (1.00) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL6609071 | 0.82 | KDR (0.75) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL22680408 | 0.82 | KDR (0.83) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL905595 | 0.81 | KDR (0.86) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL905633 | 0.80 | KDR (1.00) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL6608961 | 0.80 | KDR (1.00) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL28021677 | 0.80 | SHMT2 (0.79) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL905716 | 0.80 | KDR (0.84) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL28073018 | 0.78 | MAPT (0.64) | SHMT2KDRFLT1PDGFRBKIT | |
| SCHEMBL905634 | 0.78 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268137-B2 | Ocular therapy | NOVARTIS AG (CH) | 2007-09-11 | — | — | US | claimed |
| EP-1105136-B1 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | NOVARTIS AG (CH) | 2007-08-29 | — | — | EP | claimed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050209238-A1 | Method for treating ocular neovascular diseases | BRAZZELL ROMULUS K | 2005-09-22 | — | — | US | claimed |
| EP-0970070-B1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | claimed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | claimed |
| US-20040116434-A1 | Ocular therapy | NOVARTIS AG (CH) | 2004-06-17 | — | — | US | claimed |
| US-20040102444-A1 | Method for delivering drugs to the retina | CAMPOCHIARO PETER (US) | 2004-05-27 | — | — | US | claimed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | claimed |
| US-20030171375-A1 | Method for treating ocular neovascular diseases | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | claimed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | claimed |
| US-6271233-B1 | ADMINISTERING PHTHALAZINE DERVIVATIVES FOR TREATMENT AND PREVENTION OF RETINAL AND CHOROIDAL NEOVASCULARIZATION, EXUDATIVE AGE RELATED MACULAR DEGENERATION, PROLIFERATIVE DIABETIC RETINOPATHY, AND/OR ISCHEMIC RETINOPATHIES | CIBA VISION CORPORATION | 2001-08-07 | — | — | US | claimed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | claimed |
| EP-1105136-A2 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | Novartis AG (CH) | 2001-06-13 | — | — | EP | claimed |
| WO-2000009098-A2 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | claimed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | claimed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SHMT2 18/4885KDR 3803/4885FLT1 3556/4885 |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | SHMT2 575/4885KDR 10/4885FLT1 4/4885 |
| US-20030171375-A1 | Method for treating ocular neovascular diseases | ALDH1A2, VEGFA, FLT4 | SHMT2 2768/4885KDR 4/4885FLT1 5/4885 |
| US-20050209238-A1 | Method for treating ocular neovascular diseases | ALDH1A2, VEGFA, FLT4 | SHMT2 2768/4885KDR 4/4885FLT1 5/4885 |
| US-20040102444-A1 | Method for delivering drugs to the retina | ALDH1A2, NR2E3, STRA6 | SHMT2 779/4885KDR 121/4885FLT1 909/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | SHMT2 643/4885KDR 16/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.